Nkarta, INC 8-K filings

Nkarta, Inc. announced its second quarter 2026 financial results, detailing continued patient enrollment in its autoimmune disease trials and a cash runway extending into 2029.

Nkarta, Inc. stockholders re-elected two Class III directors and ratified the appointment of Ernst & Young LLP at the 2026 Annual Meeting.

Nkarta announced first quarter 2026 financial results, highlighting progress in its NKX019 clinical program for autoimmune diseases and a cash runway extending into 2029.

Nkarta, Inc. announced its fourth quarter and full year 2025 financial results, highlighting advancement of its NKX019 clinical program and an extended cash runway into 2029.

Nkarta, Inc. announced its third quarter 2025 financial results, highlighting clinical progress for NKX019 in autoimmune diseases and extending its cash runway into 2029.

Nkarta, Inc. announced its second quarter 2025 financial results, reporting a reduced net loss and extending its cash runway into 2029, alongside progress in its NKX019 autoimmune clinical programs.

Nkarta, Inc. announced a significant leadership transition with the appointment of Shawn Rose as Chief Medical Officer and Head of R&D, signaling a strategic pivot towards autoimmune disease, alongside the ratification of director elections and auditor appointment at its annual meeting.

Nkarta, a clinical-stage biopharmaceutical company, announced its Q1 2025 financial results, highlighting progress in clinical trials for NK cell therapies and a cash runway extending into 2029.

Nkarta is restructuring, reducing its workforce by 34%, and focusing on its NKX019 program for autoimmune diseases, which is expected to extend its cash runway into 2029.

Nkarta shifts focus to autoimmune disease, reporting a $405.3 million cash balance and plans to initiate Ntrust-2 enrollment by year-end 2024.

Nkarta announced its second quarter 2024 financial results, progress in clinical trials for its NK cell therapies, and a strong cash position to fund operations into late 2027.

Nkarta reported its second quarter 2024 financial results, highlighted by a strong cash position and progress in clinical trials for its NK cell therapies.

Nkarta, a biopharmaceutical company, has appointed Nadir Mahmood as President and made other leadership changes to enhance its development of NK cell therapies.

Nkarta has received FDA clearance to expand the clinical development of NKX019 to include systemic sclerosis, idiopathic inflammatory myopathy, and ANCA-associated vasculitis, while also initiating a clinical trial for lupus nephritis.

Nkarta, Inc. has increased its authorized common stock shares and appointed Dr. George Vratsanos to its board of directors.

Nkarta announced its first quarter 2024 financial results, highlighted by a strong cash position of $450 million and progress in its NK cell therapy programs.

Nkarta, Inc. successfully raised approximately $225.2 million through the issuance of common stock and pre-funded warrants.

Nkarta, Inc. shared updated clinical data on NKX019, demonstrating rapid depletion of CD19 positive cells and subsequent recovery of a naive B-cell population, along with comparable pharmacokinetic exposure with different lymphodepletion regimens.

Nkarta is focusing on its NKX019 program for autoimmune diseases, with first patient dosing expected in the first half of 2024, while deprioritizing NKX101 development.